Browsing Tag
AtaiBeckley
2 posts
Eli Lilly revenue surges 39% to $24.4bn, but drug pricing and acquisition charges test earnings
Eli Lilly raised its 2026 revenue guidance to $91 billion to $92 billion after strong diabetes and obesity medicine sales. However, a 15% decline in realised prices and substantial acquired research charges complicate the outlook for earnings growth.
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029.